ISONIAZID; RIFAMPIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for isoniazid; rifampin and what is the scope of patent protection?
Isoniazid; rifampin
is the generic ingredient in two branded drugs marketed by Sanofi Aventis Us and Hikma Intl Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.Summary for ISONIAZID; RIFAMPIN
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 52 |
Patent Applications: | 19 |
DailyMed Link: | ISONIAZID; RIFAMPIN at DailyMed |
Recent Clinical Trials for ISONIAZID; RIFAMPIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tuberculosis Trials Consortium | Phase 2/Phase 3 |
First Affiliated Hospital of Zhejiang University | Phase 3 |
Instituto de Salud Carlos III | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for ISONIAZID; RIFAMPIN
US Patents and Regulatory Information for ISONIAZID; RIFAMPIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sanofi Aventis Us | RIFAMATE | isoniazid; rifampin | CAPSULE;ORAL | 061884-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hikma Intl Pharms | RIFAMPIN AND ISONIAZID | isoniazid; rifampin | CAPSULE;ORAL | 065221-001 | Jul 29, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |